» Articles » PMID: 16859527

Hepatocyte Growth Factor Prevents Lupus Nephritis in a Murine Lupus Model of Chronic Graft-versus-host Disease

Overview
Publisher Biomed Central
Specialty Rheumatology
Date 2006 Jul 25
PMID 16859527
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic graft-versus-host disease (GVHD) induced in (C57BL/6 x DBA/2) F1 (BDF1) mice by the injection of DBA/2 mouse spleen cells represents histopathological changes associated with systemic lupus erythematosus (SLE), primary biliary cirrhosis (PBC) and Sjogren's syndrome (SS), as indicated by glomerulonephritis, lymphocyte infiltration into the periportal area of the liver and salivary glands. We determined the therapeutic effect of hepatocyte growth factor (HGF) gene transfection on lupus using this chronic GVHD model. Chronic GVHD mice were injected in the gluteal muscle with either HVJ liposomes containing 8 microg of the human HGF expression vector (HGF-HVJ liposomes) or mock vector (untreated control). Gene transfer was repeated at 2-week intervals during 12 weeks. HGF gene transfection effectively prevented the proteinuria and histopathological changes associated with glomerulonephritis. While liver and salivary gland sections from untreated GVHD mice showed prominent PBC- and SS-like changes, HGF gene transfection reduced these histopathological changes. HGF gene transfection greatly reduced the number of splenic B cells, host B cell major histocompatibility complex class II expression, and serum levels of IgG and anti-DNA antibodies. IL-4 mRNA expression in the spleen, liver, and kidneys was significantly decreased by HGF gene transfection. CD28 expression on DBA/2 CD4+ T cells was decreased by the addition of recombinant HGF in vitro. Furthermore, IL-4 production by DBA/2 CD4+ T cells stimulated by irradiated BDF1 dendritic cells was significantly inhibited by the addition of recombinant HGF in vitro. These results suggest that HGF gene transfection inhibited T helper 2 immune responses and reduced lupus nephritis, autoimmune sialoadenitis, and cholangitis in chronic GVHD mice. HGF may represent a novel strategy for the treatment of SLE, SS and PBC.

Citing Articles

Spatial characterization of interface dermatitis in cutaneous lupus reveals novel chemokine ligand-receptor pairs that drive disease.

Shakiba S, Haddadi N, Afshari K, Lubov J, Raef H, Li R bioRxiv. 2024; .

PMID: 38260617 PMC: 10802382. DOI: 10.1101/2024.01.05.574422.


Construction of HGF-Displaying Yeast by Cell Surface Engineering.

Shibasaki S, Nakatani Y, Taketani K, Karasaki M, Matsui K, Ueda M Microorganisms. 2022; 10(7).

PMID: 35889092 PMC: 9316346. DOI: 10.3390/microorganisms10071373.


Mesenchymal Stromal Cells Modulate Corneal Alloimmunity via Secretion of Hepatocyte Growth Factor.

Mittal S, Foulsham W, Shukla S, Elbasiony E, Omoto M, Chauhan S Stem Cells Transl Med. 2019; 8(10):1030-1040.

PMID: 31179638 PMC: 6766689. DOI: 10.1002/sctm.19-0004.


Hepatocyte growth factor is a potential biomarker for osteoproliferation and osteoporosis in ankylosing spondylitis.

Torres L, Klingberg E, Nurkkala M, Carlsten H, Forsblad-dElia H Osteoporos Int. 2018; 30(2):441-449.

PMID: 30306221 PMC: 6449322. DOI: 10.1007/s00198-018-4721-4.


The Impact of the Epithelial-Mesenchymal Transition Regulator Hepatocyte Growth Factor Receptor/Met on Skin Immunity by Modulating Langerhans Cell Migration.

Sagi Z, Hieronymus T Front Immunol. 2018; 9:517.

PMID: 29616031 PMC: 5864859. DOI: 10.3389/fimmu.2018.00517.


References
1.
Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A . In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med. 1997; 3(8):894-9. DOI: 10.1038/nm0897-894. View

2.
Fujiwara H, Iwasaki T, Shearer G . Loss of proliferative capacity and T cell immune development potential by bone marrow from mice undergoing a graft-vs-host reaction. J Immunol. 1986; 137(10):3100-8. View

3.
Cohen P, Litvin D, Winfield J . Association between endogenously activated T cells and immunoglobulin-secreting B cells in patients with active systemic lupus erythematosus. Arthritis Rheum. 1982; 25(2):168-73. DOI: 10.1002/art.1780250209. View

4.
de Wit D, Van Mechelen M, Zanin C, Doutrelepont J, Velu T, Gerard C . Preferential activation of Th2 cells in chronic graft-versus-host reaction. J Immunol. 1993; 150(2):361-6. View

5.
Via C, Rus V, Gately M, Finkelman F . IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease. J Immunol. 1994; 153(9):4040-7. View